---
title: 'Manufacturing Daily Summary: What Happened on October 21, 2026'
headline: Cost Plus Drugs tests custom rare-disease medicines at its Dallas factory
description: The shipments were the first test of a plan to change how custom treatments
are made and sold.
url: https://thebench.bio/news/manufacturing/2026-10-21
topic: manufacturing
date: '2026-10-21'
covers:
- '2026-10-21'
date_published: '2026-10-21T12:04:24Z'
date_modified: '2026-10-21T12:04:24Z'
tags:
- Industry
sources: 1
publisher: TheBench.Bio
---
# Manufacturing Daily Summary: What Happened on October 21, 2026
**Cost Plus Drugs tests custom rare-disease medicines at its Dallas factory**
The shipments were the first test of a plan to change how custom treatments are made and sold.
## Today in brief
Cost Plus Drugs’ Dallas factory received shipments of custom medicines for rare diseases, the first test of a plan to change how they are made and sold. [1] One shipment contained molecules aimed at a genetic mutation affecting one patient’s neurons. Another was developed to treat a disease that progressively impairs adults’ muscle control. [1]
## Also worth knowing
- Mark Cuban said the effort could help people with rare diseases. He has spent five years trying to lower the cost of generic medicines. [1]
## Also published
- [Pharma’s supplier sprawl problem: When more vendors create less control](), Pharmaceutical Technology
- [Scalable hPSC manufacturing: seamless 2D to 3D cell culture](), BioTechniques
## Sources
1. [STAT+: Mark Cuban wants to crack open the market for rare disease treatments](), STAT Biotech, 2026-10-21
---
TheBench.Bio wrote this from the reporting cited above, with a language model drafting and editing.
[1]: